SAN DIEGO, May 5 (UPI) -- Bio-Matrix Scientific Group has submitted a proposal to the U.S. Army in a move to gain funding approval for traumatic brain injury treatment research.
U.S. company Bio-Matrix Scientific Group, also known as BMSN, said it has jointly submitted a project summary report with its Entest BioMedical subsidiary to the Army Medical Research and Materiel Command. BMSN and Entest BioMedical said the project summary report proposal offers a new approach to traumatic brain injury treatment through advancements in regenerative medicine.
BMSN said the proposal, if approved by the Army Medical Research and Materiel Command, would fund further study of the therapeutic potential of adipose-derived stem cells. Officials said the study is part of an effort to address the increase in traumatic brain injuries of soldiers returning from Iraq and Afghanistan.
"The objective of our proposal is to develop an effective (adipose-derived stem cells)-based therapy for (traumatic brain injury)," David Koos, BMSN chairman and chief executive, said in a statement.
According to a BMSN news release, "Adipose, or fat, tissue is the most abundant and accessible source of adult stem cells that can be easily harvested from liposuction and can also differentiate into neural cells."
